About Incyte Corporation
https://www.incyte.comIncyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
CEO
Herve Hoppenot
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-09-01 | Forward | 2:1 |
| 1997-11-10 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 717
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Guggenheim
Buy
Stifel
Buy
B of A Securities
Buy
Citigroup
Buy
Mizuho
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:30.74M
Value:$3.26B
BLACKROCK INC.
Shares:21.36M
Value:$2.26B
VANGUARD GROUP INC
Shares:19.95M
Value:$2.11B
Summary
Showing Top 3 of 938
About Incyte Corporation
https://www.incyte.comIncyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.37B ▲ | $823.46M ▲ | $424.17M ▲ | 31.05% ▼ | $2.17 ▲ | $506.92M ▼ |
| Q2-2025 | $1.22B ▲ | $809.02M ▲ | $405M ▲ | 33.32% ▲ | $2.09 ▲ | $581.52M ▲ |
| Q1-2025 | $1.05B ▼ | $746.61M ▼ | $158.2M ▼ | 15.03% ▼ | $0.82 ▼ | $257.21M ▼ |
| Q4-2024 | $1.18B ▲ | $776.11M ▼ | $201.21M ▲ | 17.07% ▲ | $1.04 ▲ | $336.88M ▲ |
| Q3-2024 | $1.14B | $865.96M | $106.46M | 9.36% | $0.55 | $179.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.93B ▲ | $6.33B ▲ | $1.68B ▲ | $4.65B ▲ |
| Q2-2025 | $2.42B ▲ | $5.82B ▲ | $1.65B ▼ | $4.17B ▲ |
| Q1-2025 | $2.41B ▲ | $5.75B ▲ | $2.08B ▲ | $3.67B ▲ |
| Q4-2024 | $2.16B ▲ | $5.44B ▲ | $2B ▲ | $3.45B ▲ |
| Q3-2024 | $1.77B | $5.01B | $1.84B | $3.17B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $424.17M ▲ | $559.39M ▲ | $-47.42M ▼ | $-12.78M ▼ | $500.04M ▲ | $544.64M ▲ |
| Q2-2025 | $405M ▲ | $44.74M ▼ | $-18.87M ▼ | $-11.25M ▲ | $13.43M ▼ | $25.67M ▼ |
| Q1-2025 | $158.2M ▼ | $266.07M ▼ | $1.1M ▲ | $-12.68M ▼ | $253.94M ▼ | $262.9M ▼ |
| Q4-2024 | $201.21M ▲ | $381.22M ▲ | $-21.46M ▼ | $20.39M ▲ | $383.61M ▲ | $363.83M ▲ |
| Q3-2024 | $106.46M | $310.87M | $38.27M | $-32.35M | $316.92M | $293.18M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 I C L U S I G | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ | $30.00M ▼ |
 J A K A F I | $2.91Bn ▲ | $870.00M ▼ | $920.00M ▲ | $800.00M ▼ |
 M I N J U V I | $30.00M ▲ | $30.00M ▲ | $40.00M ▲ | $30.00M ▼ |
 Milestone And Contract Revenue | $0 ▲ | $10.00M ▲ | $40.00M ▲ | $0 ▼ |
 Olumiant Royalty | $40.00M ▲ | $30.00M ▼ | $40.00M ▲ | $30.00M ▼ |
 OPZELURA | $160.00M ▲ | $160.00M ▲ | $190.00M ▲ | $120.00M ▼ |
 PEMAZYRE Royalty Revenues | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 Tabrecta Royalty Revenues | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 ZYNYZ | $0 ▲ | $10.00M ▲ | $20.00M ▲ | $0 ▼ |
Revenue by Geography
| Region | Q4-2019 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Europe | $0 ▲ | $70.00M ▲ | $80.00M ▲ | $100.00M ▲ |
 US | $0 ▲ | $980.00M ▲ | $1.13Bn ▲ | $1.26Bn ▲ |
 NonUS | $90.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Herve Hoppenot
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2000-09-01 | Forward | 2:1 |
| 1997-11-10 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 717
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Guggenheim
Buy
Stifel
Buy
B of A Securities
Buy
Citigroup
Buy
Mizuho
Outperform
Wells Fargo
Overweight
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:30.74M
Value:$3.26B
BLACKROCK INC.
Shares:21.36M
Value:$2.26B
VANGUARD GROUP INC
Shares:19.95M
Value:$2.11B
Summary
Showing Top 3 of 938